The questions now: Ronald W. Miller, Chair of the Company:
“With the successful completion of this merger, we are now optimized to bring value-driving, transformational products to the market.”
The questions now:
1) Is Ronald Miller well placed to know if AEZS has "transformational products"?
2) Are we about to see the data and events supportive of AEZS having "transformational products"? Key data and events: 1) Diagnostic data and licensing deal; 2) Successful PGX scale-up to 50L and 100L plus licensing deal; 3) Preliminary safety/tolerability, efficacy data for avenanthramide; 4) Peer-reviewed comprehensive data for PGX-YBG/Fibrosis and clinical trial 'go' decision; 5) Final data from the Angiogenesis Foundation for wound healing and potential partnership; 6) NMOSD data, lead candidate selection, and regulatory path forward.
3) Are the "transformational products" and the path forward priced into the stock? Will we be "thrilled".